Payment overview · 2025
General Payments
$4,026.44
102 reported records · 17 companies
Healthcare provider profile · identity verified
Crystal Howlett, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LOUISVILLE, KY · NPI 1659045805
Verified facts
What the public records show
CMS Open Payments records show Crystal Howlett, APRN received $4,026.44 in general payments during 2025 across 102 reported records.
Lilly USA, LLC accounted for 64.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $2,590.83 | 64.3% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $203.91 | 5.1% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.28 | 4.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $170.94 | 4.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $166.48 | 4.1% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $152.73 | 3.8% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.76 | 3.5% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.65 | 2.0% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $61.12 | 1.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.03 | 1.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.60 | 0.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.43 | 0.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.62 | 0.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.21 | 0.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.20 | 0.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $31.05 | 0.8% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $14.60 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,300.00 | 3 |
| Food and Beverage | $1,464.44 | 97 |
| Travel and Lodging | $262.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $800.00 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $203.91 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $181.95 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $170.94 | 8 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $170.94 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $161.87 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $160.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $152.73 | 19 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $139.76 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.76 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $113.86 | 6 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $61.12 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $4.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $4.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 121 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 109 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 263 | 62 |
| Lisinopril | Lisinopril | 236 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 46 |
| Gabapentin | Gabapentin | 124 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 46 |
| Omeprazole | Omeprazole | 112 | 45 |
| Montelukast Sodium | Montelukast Sodium | 107 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 51 |
| Metformin Hcl | Metformin Hcl | 94 | 41 |
| Buspirone Hcl | Buspirone Hcl | 91 | 22 |
| Furosemide | Furosemide | 89 | 37 |
| Farxiga | Dapagliflozin Propanediol | 85 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 38 |
| Trazodone Hcl | Trazodone Hcl | 82 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 24 |
| Potassium Chloride | Potassium Chloride | 79 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 22 |
| Baclofen | Baclofen | 73 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 32 |
| Ozempic | Semaglutide | 66 | 17 |
| Eliquis | Apixaban | 64 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 28 |
| Sertraline Hcl | Sertraline Hcl | 63 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 18 |
| Prednisone | Prednisone | 58 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 21 |
| Alprazolam | Alprazolam | 52 | 11 |
| Meloxicam | Meloxicam | 52 | 19 |
| Azithromycin | Azithromycin | 51 | 47 |
| Famotidine | Famotidine | 49 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 28 |
| Losartan Potassium | Losartan Potassium | 45 | 18 |
| Ibuprofen | Ibuprofen | 43 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Glipizide | Glipizide | 42 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | 19 |
| Simvastatin | Simvastatin | 34 | 15 |
| Topiramate | Topiramate | 34 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Carvedilol | Carvedilol | 31 | 12 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Trulicity | Dulaglutide | 30 | 11 |
| Glipizide Er | Glipizide | 29 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Allopurinol | Allopurinol | 27 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Valsartan | Valsartan | 25 | 12 |
| Januvia | Sitagliptin Phosphate | 24 | 13 |
| Linzess | Linaclotide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | 11 |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Atenolol | Atenolol | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 12 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 17 | 15 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | 12 |
| Naproxen | Naproxen | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,026.44 · 102 records | Lilly USA, LLC | ACTHAR, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, HETLIOZ, Kerendia, MINIMED 780G, MOUNJARO, OTEZLA, Ohtuvayre, Omnipod, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error